Skip to main content

PAINWeek 2023 Main banner

Icon Legend

This session is not in your agenda.

This session is in your agenda. Click to remove it

Back

Alexis Mollard, PhD

Sr. Director Medicinal Chemistry
Halia Therapeutics
Salt Lake City, Utah

Disclosure information not submitted.

Presentation(s):

Characterization of the NLRP3 Inflammasome Inhibitor HT-6184 in the Complete Freund's Adjuvant (CFA)-Induced Pain Model
POSTER ABSTRACT